AstraZeneca and the University of Oxford have given us something to be thankful for: another COVID-19 vaccine candidate with positive interim Phase 3 results. Data showed the vaccine candidate to be 70 percent effective in protecting recipients from COVID-19. This overall effectiveness rate is based on the average of two dosing regimens explored in the trial; the vaccine was deemed 90 percent effective when distributed as a half dose followed by a full dose, and 62 percent effective when received as two full doses.
I hope each of you finds a way to safely celebrate Thanksgiving this year. No doubt any plans for travelling or gathering with loved ones looks different than in the past. Despite the challenges of this year, I remain grateful for the opportunity to serve each of you in Congress.